This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Katz, S. D. Articles by Maybaum, S. Search for Related Content PubMed PubMed Citation Articles by Katz, S. D. Articles by Maybaum, S.

Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure

^a Division of Circulatory Physiology, Columbia Presbyterian Medical Center, New York, New YorkUSA
^b Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA

View larger version (13K): [in a new window]   Figure 1 Change (means ± SEM) in flow-mediated dilation (FMD, %) from pretreatment values after release of 1, 3 and 5 min of arterial occlusion in patients treated with placebo (closed squares), sildenafil 12.5 mg (open squares), sildenafil 25 mg (open circles) and sildenafil 50 mg (open triangles).